FTC Expands PBM Settlement Talks, Setting Industry-Wide Standards

The Federal Trade Commission (FTC) is taking significant steps towards reshaping the pharmacy benefit manager (PBM) landscape. On March 3, 2026, the agency extended a stay in its administrative proceedings against OptumRx and Caremark Rx, allowing more time for settlement discussions. The parties involved reported making “significant progress” in negotiations. This development follows the FTC’s February 4, 2026 settlement with Express Scripts, Inc., which introduced a 10-year plan involving operational commitments and compliance measures related to formulary design, pricing, transparency, and compensation structures.

The FTC’s focus has shifted from a singular case to what appears to be a broader regulatory reset initiated through these settlements. The original intent of the FTC was to address how PBM rebate-driven incentives and formulary designs impact insulin access and patient costs. The details outlined in the consent order with Express Scripts have now established a comprehensive and enforceable framework. If similar agreements are reached with OptumRx and Caremark, the implications could lead to an industry-wide recalibration of how PBMs operate.

Potential Industry Impact of Harmonized Settlements

Industry experts suggest that if the FTC secures parallel commitments from the “Big Three” PBMs—Express Scripts, OptumRx, and Caremark—pressure for compliance across the sector will increase. This could lead to a unified approach towards PBM operations, impacting not only their internal processes but also their relationships with payers, manufacturers, and pharmacies.

The consent order with Express Scripts mandates the integration of the TrumpRx platform into its standard offerings for plan sponsors. This transition signifies a shift from merely debating PBM operations to a reality where the FTC defines operational parameters through negotiated settlements with major market players.

Organizations across the healthcare landscape, including PBMs, plan sponsors, payers, and manufacturers, should prepare for heightened scrutiny. The risk is not confined to a single case but extends to becoming the next focus of an emerging FTC enforcement strategy.

Recommendations for Organizations

To navigate this evolving regulatory environment, companies should take proactive measures to ensure compliance and readiness for potential investigations. Here are some recommended steps:

1. **Map List-Price Touchpoints**: Identify all revenue streams, fees, guarantees, or benchmarks linked to wholesale acquisition cost (WAC) and document the rationale behind these practices.

2. **Pressure-Test Formulary Governance**: Ensure that decision-making pathways are transparent, well-documented, and defensible, particularly in areas where rebate economics could allegedly impact patient access.

3. **Audit Transparency and Reporting Capabilities**: Confirm the ability to produce detailed reports at the drug level, examine the speed of production, and ensure that communications align with actual practices.

4. **Review Contracting and Disclosures**: Assess agreements with sponsors, manufacturers, and pharmacies for audit rights, reporting obligations, and definitions, especially in anticipation of potential market shifts.

5. **Update Investigation Response Protocols**: Revise document retention policies and communication strategies to ensure cohesive and efficient responses to inquiries from the FTC, state attorneys general, or subsequent civil litigation.

The ongoing negotiations and settlements could fundamentally reshape the landscape of pharmacy benefit management, requiring all stakeholders to remain vigilant and adaptable in this changing environment.